Glaukos says Epioxa benefits durable through three years in keratoconus
GKOS•Glaukos reported topline three-year results from a Phase 3 extension study showing sustained disease stabilization and vision benefits after one Epioxa treatment, with no serious treatment-related events.
1. Three-year follow-up
Glaukos said a Phase 3 extension study of Epioxa for keratoconus found sustained disease stabilization and meaningful vision benefits through three years after a single treatment. The company said no serious events were tied to treatment during follow-up.
